Organon & Co | OGN - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Celltrion KRW 12.71B 237.27B 2025-12
Cspc Pharmaceutical CNY 1.87B 95.62M 2025-12
Deva Holding AS TRY 462.26M 48.18M 2023-09
Dianthus Therapeutics USD 6.57M 1.62M 2025-12
Divis Laboratories Ltd INR 3.4B 10M 2025-06
Gilead Sciences USD 1.45B 326M 2026-03
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Kangmei Pharma CNY 237.06M 37.35M 2026-03
Knight Therapeutics CAD 35.45M 4.43M 2025-12
Laboratorios Farma EUR 35.32M 2.75M 2025-06
Malin Corporation EUR 1.1M 400K 2024-12
Medical Developments International AUD 2.84M 4.19M 2025-12
Merck USD 2.67B 180M 2026-03
Neuren Pharmaceuticals AUD 3.74M 2.5M 2025-12
Novartis USD 3.44B 132M 2025-12
Organigram Holdings CAD 7.73M 1.13M 2025-12
Organon & Co USD 433M 34M 2025-12
Ovoca Bio EUR 632K 2.33M 2025-06
Pharma Mar EUR 15.31M 2M 2026-03
Qiagen NV USD 153.88M 10.77M 2025-12
Sartorius EUR 221.3M 500K 2026-03
Sino Biopharmaceutical CNY 7.54B 2.23B 2025-06
Tilray USD 24.85M 1.7M 2025-09
Zealand Pharma A/S 91.81M 99.04M 2025-12